321 related articles for article (PubMed ID: 23075373)
21. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.
Dekempeneer Y; Keyaerts M; Krasniqi A; Puttemans J; Muyldermans S; Lahoutte T; D'huyvetter M; Devoogdt N
Expert Opin Biol Ther; 2016 Aug; 16(8):1035-47. PubMed ID: 27145158
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and preliminary evaluation of
Vaidyanathan G; Mease RC; Minn I; Choi J; Chen Y; Shallal H; Kang CM; McDougald D; Kumar V; Pomper MG; Zalutsky MR
Nucl Med Biol; 2021; 94-95():67-80. PubMed ID: 33601187
[TBL] [Abstract][Full Text] [Related]
23. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
24. Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates.
Teze D; Sergentu DC; Kalichuk V; Barbet J; Deniaud D; Galland N; Maurice R; Montavon G
Sci Rep; 2017 May; 7(1):2579. PubMed ID: 28566709
[No Abstract] [Full Text] [Related]
25. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Wüstemann T; Barelli P; Kim D; Williams C; Zheng X; Bi C; Hu B; Warren JD; Hage DS; DiMagno SG; Babich JW
J Nucl Med; 2017 Sep; 58(9):1442-1449. PubMed ID: 28450562
[TBL] [Abstract][Full Text] [Related]
26. Actinium-225 in targeted alpha-particle therapeutic applications.
Scheinberg DA; McDevitt MR
Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
[TBL] [Abstract][Full Text] [Related]
27. Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy.
Ogawa K; Mizuno Y; Washiyama K; Shiba K; Takahashi N; Kozaka T; Watanabe S; Shinohara A; Odani A
Nucl Med Biol; 2015 Nov; 42(11):875-9. PubMed ID: 26235266
[TBL] [Abstract][Full Text] [Related]
28. Targeted cancer cell ablation in mice by an α-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B.
Li HK; Hasegawa S; Nakajima NI; Morokoshi Y; Minegishi K; Nagatsu K
Biochem Biophys Res Commun; 2018 Dec; 506(4):1078-1084. PubMed ID: 30409432
[TBL] [Abstract][Full Text] [Related]
29. An Appendix of Radionuclides Used in Targeted Alpha Therapy.
Ferrier MG; Radchenko V
J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S58-S65. PubMed ID: 31427258
[No Abstract] [Full Text] [Related]
30. Development of
Robertson AKH; Ramogida CF; Schaffer P; Radchenko V
Curr Radiopharm; 2018; 11(3):156-172. PubMed ID: 29658444
[TBL] [Abstract][Full Text] [Related]
31. Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy.
Chouin N; Lindegren S; Jensen H; Albertsson P; Bäck T
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):487-95. PubMed ID: 23358400
[TBL] [Abstract][Full Text] [Related]
32. Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213.
Lucignani G
Eur J Nucl Med Mol Imaging; 2008 Sep; 35(9):1729-33. PubMed ID: 18542953
[No Abstract] [Full Text] [Related]
33. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
[TBL] [Abstract][Full Text] [Related]
34. The advantage of antibody cocktails for targeted alpha therapy depends on specific activity.
Pasternack JB; Domogauer JD; Khullar A; Akudugu JM; Howell RW
J Nucl Med; 2014 Dec; 55(12):2012-9. PubMed ID: 25349219
[TBL] [Abstract][Full Text] [Related]
35. Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer.
Allen BJ
Australas Radiol; 1999 Nov; 43(4):480-6. PubMed ID: 10901964
[TBL] [Abstract][Full Text] [Related]
36. Production of α-particle emitting ²¹¹At using 45 MeV α-beam.
Kim G; Chun K; Park SH; Kim B
Phys Med Biol; 2014 Jun; 59(11):2849-60. PubMed ID: 24819557
[TBL] [Abstract][Full Text] [Related]
37. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
[TBL] [Abstract][Full Text] [Related]
38. Overcoming the obstacles to clinical evaluation of (211)At-labeled radiopharmaceuticals.
Wilbur DS
J Nucl Med; 2001 Oct; 42(10):1516-8. PubMed ID: 11585866
[No Abstract] [Full Text] [Related]
39. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.
Pozzi OR; Zalutsky MR
J Nucl Med; 2007 Jul; 48(7):1190-6. PubMed ID: 17574991
[TBL] [Abstract][Full Text] [Related]
40. New method for production of
Moiseeva AN; Aliev RA; Furkina EB; Novikov VI; Unezhev VN
Nucl Med Biol; 2022; 106-107():52-61. PubMed ID: 35032789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
